Antivascular and Antitumor Activities of Liposome-associated Drugs

Anticancer Research

Volumn 24, Issue 2 A, 2004, Pages 397-404

  Straubinger, Robert M ^a   Arnold, Robert D ^a   Zhou, Rong ^b,c   Mazurchuk, Richard ^b   Slack, Jeanine E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer chemotherapy; Doxorubicin; Drug delivery; Liposomes; Paclitaxel; Physiological modeling

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CAELIX; CREMOPHOR; DOXORUBICIN; DRUG CARRIER; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCOCORTICOID; LIPOSOME; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER; CANCER CHEMOTHERAPY; COLLAPSE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SLOW DRUG RELEASE; STEREOCHEMISTRY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS; LIPOSOMES;

EID: 2442490090     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB and Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743, 1999.
2. Legler JM, Gloeckler Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan, RS and Linet MS: Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91: 1382-1390, 1999.
3. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L and Edwards BK: Surveillance Epidemiology End Result (SEER) Cancer Statistics Review 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
4. Packer RJ: Brain tumors in children. Arch Neurol 56: 421-425, 1999.
5. Fathallah-Shaykh H: New molecular strategies to cure brain tumors. Arch Neurol 56: 449-453, 1999.
6. Avgeropoulos NG and Batchelor TT: New treatment strategies for malignant gliomas. Oncologist 4: 209-224, 1999.
7. Jain RK: 1995 Whitaker Lecture: Delivery of molecules, particles, and cells to solid tumors. Ann Biomed Eng 24: 457-473, 1996.
8. Jain RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9: 253-266,1990.
9. Guastalla JP, Lhomme C, Dauplat J, Namer M, Bonneterre J, Oberling F, Poulliart P, Fumoleau P, Kerbrat P and Tubiana N: Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. Annals Oncol 5: S33-38, 1994.
10. Kubota T, Matsuzaki SW, Hoshiya Y, Watanabe M, Kitajima M, Asanuma F, Yamada Y and Koh JI: Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64: 115-121, 1997.
11. Adler LM, Herzog TJ, Williams S, Rader JS and Mutch DG: Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer 74: 1891-1898, 1994.
12. Sharma A, Mayhew E and Straubinger RM: Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 53: 5877-5881, 1993.
13. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H and Raber MN: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993.
14. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, VanEcho DA, VonHoff DD and Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268, 1990.
15. Szebeni J, Muggia FM and Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Nat Cancer Inst 90: 300-306, 1998.
16. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G and Sparreboom A: Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47: 309-318, 2001.
17. Bookman MA, Kloth DD, Kover PE, Smolinski S and Ozols RF: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8: 611-614, 1997.
18. Jamis-Dow CA, Klecker RW, Katki AG and Collins JM: Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 36: 107-114, 1995.
19. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G and Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454-1457, 1999.
20. Ellis AG and Webster LK: Inhibition of pactitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 43: 13-18, 1999.
21. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, de Vos AI, Nooter K, Stoter G and Gianni L: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937-1942, 1998.
22. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ and Beijnen JH: Cremophor EL. causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330-335, 1999.
23. Cahan MA, Walter KA, Colvin OM and Brem H: The cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33: 441-444, 1994.
24. Liebmann JE, Cook JA, Lipschulz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109, 1993.
25. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C and Potier P: Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 17: 137-142, 1986.
26. Riondel J, Jacrot M, Fessi H, Puisieux F and Poiter P: Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6: 23-28, 1992.
27. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, Faibel M, Nass D, Hadani M, Orenstein A, Cohen JS and Ram Z: Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61: 4971-4497 4973, 2001.
28. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L and Kadota R: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Ped Hemat/Oncol 23: 277-281, 2001.
29. Chang SM, Kuhn JG, Robins HI, Schold SC, Jr Spence AM, Berger MS, Mehta M, Pollack IF, Rankin C and Prados MD: A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 91: 417-422, 2001.
30. Postma TJ, Heimans JJ, Luykx SA, van Groeningen CJ, Beenen LF, Hoekstra OS, Taphoorn MJ, Zonnenberg BA, Klein M and Vermorken JB: A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol 11: 409-413, 2000.
31. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P and Egorin MJ: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87: 1077-1081, 1995.
32. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss, T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A and Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110: 1309-1318, 2002.
33. Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP and Brem H: Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neuro-Oncol 58: 115-123, 2002.
34. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
35. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
36. Milas L, Hunter NR, Mason KA, Kurdoglu B and Peters LJ: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54: 3506-3510, 1994.
37. Tishler RB, Geard CR, Jall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
38. Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E and Egorin MJ: Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14: 600-609, 1996.
39. Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G and Kiss R: Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharm Tox Meth 43: 15-24, 2000.
40. Satoh H, Ishikawa H, Fujimoto M, Fujiwara M, Yamashita YT, Yazawa T, Ohtsuka M, Hasegawa S and Kamma H: Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines. Anticancer Res 18: 1027-1030, 1998.
41. Sharma A, Sharma US and Straubinger RM: Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett 107: 265-272, 1996.
42. Sharma A, Straubinger RM, Ojima I and Bernacki RJ: Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84: 1400-1404, 1995.
43. Cabanes A, Briggs KE, Gokhale PC, Treat JA and Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 12: 1035-1040, 1998.
44. Treat J, Damjanov N, Huang C, Zrada S and Rahman A: Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntington) 15: 44-48, 2001.
45. Straubinger RM, Sharma A, Murray M and Mayhew E: Novel taxol formulations: taxol-containing liposomes. J Nat Cancer Inst Monographs 15: 69-78, 1993.
46. Fetterly GJ and Straubinger RM: Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm Sci 5 (4): Article 31, 2003.
47. Zhou R, Mazurchuk RV, Tamburlin J and Straubinger RM: Efficacy of liposomal paclitaxel in an intracranial rat brain tumor model. Submitted, 2003s.
48. Straubinger RM, Sharma A, Sharma US and Balasubramanian SV: Pharmacology and antitumor effect of novel taxol formulations. In: Georg G, Chen TT, Ojima I Vyas D (eds.), Taxane Anticancer Agents: Basic Science and Current Status, pp. 111-123. Washington, DC: ACS Symposium Series, 1995.
49. Sharma US, Sharma A, Chau RI and Straubinger RM: Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14: 992-998, 1997.
50. Sharma A and Straubinger RM: Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 11: 889-896, 1994.
51. Jang SH, Wientjes MG and Au JL: Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 296; 1035-1042, 2001.
52. Kuh HJ, Jang SH, Wientjes MG, Weaver JR and Au JL: Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 290: 871-880, 1999.
53. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD and Jain RK: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59: 3776-3782, 1999.
54. Wang J, Lou P, Lesniewski R and Henkin J: Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14: 13-19, 2003.
55. Allen TM and Chonn A: Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223: 42-46, 1987.
56. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD and Redemann C: Sterically-stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Nat Acad Sci USA 88: 11460-11464, 1991.
57. Haran G, Cohen R, Bar LK and Barenholz Y: Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215, 1993.
58. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ and Cullis PR: Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH-gradients. Biochim Biophys Acta 1149: 329-348, 1993.
59. Lasic DD, Frederik PM, Stuart MC, Barenholz Y and McIntosh TJ: Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 312: 255-258, 1992.
60. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS and Perkins WR: Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415: 23-40, 1998.
61. Muggia FM: Liposomal encapsulated anthracyclines: new therapeutic horizons. Current Oncol Rep 3: 156-162, 2001.
62. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19: 424-436, 2001.
63. Gabizon A and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Nat Acad Sci USA 85: 6949-6953, 1988.
64. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D and Jain RK: Microvascular permeability and interstitial penetration of sterically-stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356, 1994.
65. Wu N, Da D, Rudoll T, Needham D, Whorton A and Dewhirst M: Increased microvascular permeability contributes to preferential accumulation of Stealth™ liposomes in tumor tissue. Cancer Res 53: 3766-3770, 1993.
66. Mazurchuk R, Zhou R, Straubinger RM, Chau RI and Grossman Z: Functional magnetic resonance (fMR) imaging of a rat brain tumor model: implications for evaluation of tumor microvasculature and therapeutic response. Magn Reson Imag 17: 537-548, 1999.
67. Zhou R, Mazurchuk RV and Straubinger RM: Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62: 2561-2566, 2002.
68. Au JL, Jang SH, Zheng J, Chen CT, Song S, Hu L and Wientjes MG: Determinants of drug delivery and transport to solid tumors. J Contr Rel 74: 31-46, 2001.
69. Au JL, Jang SH and Wientjes MG: Clinical aspects of drug delivery to tumors. J Contr Rel 78: 81-95, 2002.